A 12-week pomegranate extract trial reported a hydration signal. Understand the elasticity findings, pigmentation result and study limits.
In coverage dated October 21, 2026, NutraIngredients examined a trial of Pomanox, Euromed's standardized pomegranate extract. The paper by Costa and colleagues was published in Scientific Reports in 2026. Its primary outcome, a measure of pigmentation in a selected facial spot, did not reach statistical significance.
The more interesting signals concerned hydration and elasticity. Those results deserve attention, but they need to be read according to what was measured and which comparisons were made. That distinction matters when research becomes the basis for a beauty supplement claim.
NutraIngredients describes a randomized, triple-blind, placebo-controlled trial involving women aged 30 to 65 with hyperpigmented facial spots. According to Euromed's announcement, 66 women enrolled and 64 entered the modified intention-to-treat analysis.
Participants received 367 mg or 700 mg of Pomanox daily, or placebo, for 12 weeks. Assessments took place at baseline, week four and week 12. These are the amounts and timing used in the research, not instructions for supplement use.
The primary measurement was the change in the melanin index of a selected facial spot at 12 weeks. The researchers also assessed hydration and elasticity alongside skin and gut microbiota.
These outcomes address different questions. A pigmentation measurement concerns the selected spot, while hydration and elasticity are separate skin measurements. They should not be folded into a single claim that the extract improved every aspect of skin aging.
According to NutraIngredients, the 367 mg group had a more favorable hydration change than placebo at week 12. Hydration declined in the placebo group, while the lower-dose group maintained it.
The useful wording is therefore “maintained hydration relative to placebo,” rather than a broad claim that the supplement increased skin moisture. The comparison reflects how the groups changed over the study period. It does not mean every participant experienced the same result.
NutritionInsight and Euromed's announcement report that elasticity improved from baseline in the 700 mg group at weeks four and 12. The 367 mg group showed improvement from baseline at week 12. However, the comparison between 700 mg and placebo in the full study population showed a trend rather than a statistically conclusive difference.
“From baseline” means compared with the group's own starting measurement. A placebo comparison asks a different question: did the extract group do better than the comparison group? Improvement within a group does not answer that second question by itself.
This is why the timing of a change and the comparison behind it both matter. The results come from a controlled study, so they should not be treated as a prediction of what a person will experience in everyday use.
The small sample and single-site design limit how confidently the findings apply more widely, as the study coverage notes. The trial also concerned a particular standardized extract over a limited period. It does not establish equivalent effects for other pomegranate products or longer-term use.
The microbiota findings were exploratory. NutraIngredients and NutritionInsight describe changes involving Bifidobacterium and Lactobacillus in skin microbiota and Prevotella and Akkermansia in gut microbiota. Those observations do not establish that bacterial changes caused the hydration or elasticity findings, or that skin barrier function improved.
Seasonal context also deserves attention. Yahoo Health reports that the study ran across late autumn and winter and that facial spots faded in the placebo group too. That observation illustrates why a change during a study should not automatically be credited to the supplement. It does not identify what caused the placebo group's change.
Finally, the available reporting does not establish how noticeable the measured skin changes were in daily life. A favorable measured result and a visible improvement are different claims. That distinction remains important even when a result reaches statistical significance.
For readers considering beauty supplements, the immediate value of this trial is not a new routine. It is a useful example of how to read a claim more precisely.
Three questions help keep the evidence in focus:
These questions are not reasons to dismiss nutritional research. They are a way to recognize a potentially useful signal without turning it into a broader promise.
Younell's focus is helping readers distinguish useful evidence from marketing claims. For wider context, our guide to the structure behind skin firmness provides a broader reading path. Our coverage of quality caveats in collagen trials offers another perspective on evaluating beauty supplement evidence.
For personal decisions about supplements, a qualified clinician can help put the evidence in context. That conversation is particularly relevant when medications or existing health conditions are involved.
The open question is whether adequately powered research will reproduce the hydration finding and clarify the elasticity result. A stronger evidence base would help distinguish a repeatable benefit from a preliminary observation.
For now, this trial adds a specific clinical signal to the discussion of nutrition and skin. Its value lies in the measured findings, not in a sweeping promise about pomegranate or the microbiome.
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
